Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma Progressing on or Intolerant to Prior Treatment With Immune Checkpoint Inhibitors: A Phase II Study (Immunocabo)

NCT04435977 is registered in ClinicalTrials.gov with Istituto Clinico Humanitas as lead sponsor.

NCT NCT04435977
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04435977 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma Progressing on or Intolerant to Prior Treatment With Immune Checkpoint Inhibitors: A Phase II Study (Immunocabo)
Lead sponsor
Istituto Clinico Humanitas
Phase
Phase 2
Overall status
Unknown status
Start date
January 30, 2020
Completion date
September 30, 2023
Enrollment
46 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocarcinoma